AstraZeneca

45 YEARS
Bringing science to patients since 1979

May 26, 2026

The Manager – Listing
BSE Limited,
1st Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai 400001

The Manager – Listing
National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (E),
Mumbai 400051

Dear Sir/ Madam,

Sub: Outcome of the Board Meeting held on Tuesday, May 26, 2026

Ref: Scrip Code - BSE: 506820 / NSE: ASTRAZEN

The Board of Directors of the Company at its meeting held today i.e., May 26, 2026, has *inter-alia*:

1. Approved the Audited financial results of the Company for the quarter and financial year ended March 31, 2026. The said Audited financial results together with the Audit report of the Statutory Auditors dated May 26, 2026 are enclosed herewith.

   Further, we are arranging to publish details of the above-mentioned financial results in the newspapers as per Regulation 47 of the SEBI Listing Regulations.

2. Based on the recommendations of the Nomination and Remuneration Committee, the Board has approved the re-appointment of Ms. Shilpa Divekar Nirula (DIN 06619353) as Non-Executive, Independent Director of the Company, to hold office for a second term of 5 consecutive years with effect from December 29, 2026, subject to approval of the shareholders of the Company. Further, please find the details as required under the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 attached herewith as Annexure – A.

3. Based on the recommendations of the Audit Committee, the Board has approved the appointment of M/s. BSR & Co. LLP, Chartered Accountants (Firm Registration No. 101248W/W-100022), as the Statutory Auditors of the Company, for a term of five consecutive years, from the conclusion of the ensuing Annual General Meeting ('AGM'), i.e. the 47th AGM of the Company till the conclusion of the 52nd AGM to be held in the year 2031, subject to the approval of the shareholders. This is pursuant to the retirement of M/s. Price Waterhouse Cooper who will complete their second consecutive term as Statutory Auditors of the Company at the conclusion of the ensuing AGM. Further, please find the details as required under the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 attached herewith as Annexure – B.

4. Recommended Dividend of Rs. 36/- per equity share of face value of Rs. 2 per equity share, for the financial year 2025-26, subject to approval of the shareholders.

CORPORATE & REGD. OFFICE
AstraZeneca Pharma India Ltd.
P. B. No. 4525, Block N1, 12th Floor,
Manyata Embassy Business Park,
Rachenahalli, Outer Ring Road,
Bangalore - 560 045, INDIA

TEL : +91 80 6774 8000
FAX : +91 80 6774 8857
CIN : L24231KA1979PLC003563
WEB : www.astrazeneca.com/india

FACTORY
12th Mile on Bellary Road
Venkatala, Kattigenahalli Village
Yelahanka
Bangalore - 560 063
INDIA

TEL : +91 80 6774 9000
FAX : +91 80 2846 2208
+91 80 6774 9628

We also confirm that the Statutory Auditor's Report is with unmodified opinion in respect of the Audited financial results of the Company for the financial year ended March 31, 2026.

The press release with regard to the same is also enclosed herewith.

The meeting commenced at 2:15 P.M. and concluded at 5:10 P.M. (IST).

Please take the same on record.

Thanking you,

For **AstraZeneca Pharma India Limited**

TANYA SANISH

Digitally signed by TANYA SANISH
Date: 2026.05.26 19:08:05 +05'30'

Tanya Sanish
Company Secretary & Compliance Officer

Encl: As above

CORPORATE & REGD. OFFICE
AstraZeneca Pharma India Ltd.
P. B. No. 4525, Block N1, 12th Floor,
Manyata Embassy Business Park,
Rachenahalli, Outer Ring Road,
Bangalore - 560 045, INDIA

TEL : +91 80 6774 8000
FAX : +91 80 6774 8857
CIN : L24231KA1979PLC003563
WEB : www.astrazeneca.com/india

FACTORY
12th Mile on Bellary Road
Venkatala, Kattigenahalli Village
Yelahanka
Bangalore - 560 063
INDIA

TEL : +91 80 6774 9000
FAX : +91 80 2846 2208
+91 80 6774 9628

AstraZeneca Pharma India Limited

Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045
CIN: L24231KA1979PLC003563

Statement of financial results for the quarter and year ended 31 March 2026

Sl No.	Particulars	Quarter ended 31/03/2026	Quarter ended 31/12/2025	Quarter ended 31/03/2025	Year ended 31/03/2026	Year ended 31/03/2025
		'Rs in millions except for earnings per share data				
		Refer Note 5	Unaudited	Refer Note 5	Audited	Audited
1	**Income**					
	a) Revenue from operations	5,786.1	6,115.7	4,804.8	22,755.8	17,162.9
	b) Other income	59.5	51.3	161.5	284.9	406.3
	Total income	**5,845.6**	**6,167.0**	**4,966.3**	**23,040.7**	**17,569.2**
2	**Expenses**					
	(a) Cost of materials consumed	-	-	942.5	94.9	2,871.3
	(b) Purchase of stock-in-trade	3,123.1	6,971.2	2,878.6	18,594.2	10,088.2
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	819.4	(3,307.3)	(1,225.0)	(4,883.7)	(3,329.4)
	(d) Employee benefit expense	457.0	937.8	660.7	2,643.8	2,574.4
	(e) Depreciation and amortisation expense	56.0	38.4	176.9	285.8	399.9
	(f) Allowance for expected credit loss (net)	81.7	12.6	(9.4)	170.9	6.6
	(g) Selling, marketing and distribution expense	301.3	358.4	220.2	1,160.0	848.7
	(h) Other expenses	394.5	694.7	473.5	2,355.4	1,563.4
	(i) Finance costs	20.4	10.6	6.8	44.9	14.6
	Total expenses	**5,253.4**	**5,716.4**	**4,124.8**	**20,466.2**	**15,037.7**
3	**Profit before exceptional items and tax (1-2)**	**592.2**	**450.6**	**841.5**	**2,574.5**	**2,531.5**
4	Add/(Less): Exceptional items (Refer Note 6)	(10.8)	14.8	(56.8)	(52.5)	(967.9)
5	**Profit before tax (3+4)**	**581.4**	**465.4**	**784.7**	**2,522.0**	**1,563.6**
6	**Tax expense**					
	(a) Current tax	140.3	40.0	229.2	591.4	601.0
	(b) Tax expense for prior years	2.8	-	-	2.8	4.4
	(c) Deferred tax charge / (credit)	(10.5)	99.5	(27.0)	52.6	(199.2)
	Total tax expense	**132.6**	**139.5**	**202.2**	**646.8**	**406.2**
7	**Profit after tax (5-6)**	**448.8**	**325.9**	**582.5**	**1,875.2**	**1,157.4**
8	**Other comprehensive income/ (loss)**					
	Items that will not be reclassified to profit or loss					
	(a) Re-measurement gains / (losses) on post employment benefit obligations	(63.6)	0.1	19.6	(59.4)	(15.6)
	(b) Income tax effect on above	16.0	0.0	(5.0)	15.0	3.9
	Other comprehensive income/ (loss), net of income tax	**(47.6)**	**0.1**	**14.6**	**(44.4)**	**(11.7)**
9	**Total comprehensive income for the year/ period (7+8)**	**401.2**	**326.0**	**597.1**	**1,830.8**	**1,145.7**
10	**Paid-up equity share capital** (Face value of Rs 2/- per equity share)	**50.0**	**50.0**	**50.0**	**50.0**	**50.0**
11	**Other Equity**	-	-	-	8,677.9	7,653.5
12	**Earnings per equity share of Rs 2/- each (basic and diluted)**	**17.95**	**13.04**	**23.30**	**75.01**	**46.30**

PA

AstraZeneca Pharma India Limited Bangalore

Price Waterhouse & Co Chartered Accountants LLP LLPIN AAB-4362 FRN 304026E/E300009 Bengaluru

Initialled For Identification Purpose Only

AstraZeneca Pharma India Limited
Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045

CIN: L24231KA1979PLC00356J

Statement of financial results for the quarter and year ended 31 March 2026

Notes:

1. The Statements of financial results have been prepared in accordance with the applicable Indian Accounting Standards notified under Section 133 of the Companies Act, 2013 (the "Act") [Companies (Indian Accounting Standards) Rules, 2015 (as amended)] and other accounting principles generally accepted in India

2. The Company has identified 'Healthcare Segment' as its only reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly, no segment information has been provided

3. During an earlier year, the Company had made an announcement to Stock exchanges about its intention to exit the Company's manufacturing site in Bangalore in due course of time. The Company had subsequently started exploring the option to sell the manufacturing site in a fully operational manner to a Contract Manufacturing Organization (CMO). However, on June 21, 2024, the Board resolved that the Company would instead, explore to find a suitable buyer for its manufacturing site and exit in due course. During the quarter ended 30 June 2025, the operations at the manufacturing site have ceased and the Company is now in the process of sale of assets related to the manufacturing site. Accordingly, the Company has classified the relevant assets as "Assets classified as held for sale", in line with the requirements of relevant Accounting Standards

4. Pursuant to the notification by the Ministry of Labour & Employment on November 21, 2025 on the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as "the Labour Codes"), the Company has recognized provision towards past service cost on gratuity and compensated absences payable to employees amounting to Rs. 278.3 Million for the quarter ended December 31, 2025 and year ended March 31, 2026 which is included under "Employee benefits expense". The Company will continue to monitor the finalisation of State Rules and clarifications from the Government in this regard and would provide appropriate accounting effect on the basis of such developments as needed

5. The figures for the quarter ended 31 March 2026 and 31 March 2025 are the balancing figures between the audited figures in respect of the full financial years and the published unaudited year-to-date figures up to the third quarter of the respective financial years which were subjected to limited review by the statutory auditors

6. Exceptional Items;

a. Exceptional items for the quarter ended 31 March 2026 , 31 December 2025 and 31 March 2025 and year ended 31 March 2026 consists of expenses related to closure of the manufacturing site (Refer Note 3 above)

b. The exceptional items during the year ended 31 March 2025 also consists of employee separation cost amounting to Rs. 331.5 Million for restructuring of Biopharmaceuticals Business Unit in line with strategy of the Company to become a specialist focussed organisation, bring innovative medicines faster and transform patient outcome

7. The Board of Directors, at its meeting dated 26 May 2026, have recommended a final dividend of Rs 36 per equity share aggregating to Rs 900 Million which is subject to approval of shareholders at the ensuing Annual General Meeting

8. This Statement of financial results, Statement of assets and liabilities and Statement of cash flows were reviewed and recommended by the Audit Committee of the Board and subsequently approved by the Board of Directors at their respective meetings held on 26 May 2026

AstraZeneca Pharma India Limited Bangalore

By Order of the Board of Directors
For AstraZeneca Pharma India Limited

Praveen Akkinepally

Praveen Rao Akkinepally
Managing Director

Place: Bengaluru
Date: 26 May 2026

Price Waterhouse & Co Chartered Accountants LLP
LLPIN AAC-4362
FRN 304026E/E300009
Bengaluru

Initialled For Identification Purpose Only

AstraZeneca Pharma India Limited

Regd Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045

CIN: L24231KA1979PLC003563

Statement of assets and liabilities

(Rs. in millions)

Sl.No.	Balance Sheet	As at 31 March 2026 Audited	As at 31 March 2025 Audited
	ASSETS		
1	**Non-current assets**		
	(a) Property, plant and equipment	46.7	278.8
	(b) Right-of-use assets	1,128.0	357.0
	(c) Capital work-in-progress	-	0.0
	(d) Intangible assets	-	6.6
	(e) Financial Assets		
	(i) Loans	-	1.1
	(ii) Other financial assets	134.1	80.3
	(f) Current tax assets (net) (non-current)	789.2	602.6
	(g) Deferred tax assets (net)	378.0	415.6
	(h) Other non-current assets	15.7	15.7
	Sub-total - Non-current assets	**2,491.7**	**1,757.7**
2	**Current assets**		
	(a) Inventories	10,273.3	5,485.0
	(b) Financial Assets		
	(i) Trade receivables	2,136.8	1,848.8
	(ii) Cash and cash equivalents	4,477.2	5,361.4
	(iii) Bank balances other than cash and cash equivalents	9.0	5.6
	(iv) Loans	-	3.0
	(v) Other financial assets	87.4	158.0
	(c) Other current assets	338.2	561.7
	Current assets excluding assets classified as held for sale	**17,321.9**	**13,423.5**
	Assets classified as held for sale (Refer Note 3)	77.4	-
	Sub-total - Current assets	**17,399.3**	**13,423.5**
	TOTAL - ASSETS	**19,891.0**	**15,181.2**
	EQUITY AND LIABILITIES		
1	**Equity**		
	(a) Equity Share capital	50.0	50.0
	(b) Other Equity	8,677.9	7,653.5
	TOTAL EQUITY	**8,727.9**	**7,703.5**
	LIABILITIES		
2	**Non-current liabilities**		
	(a) Financial Liabilities		
	(i) Lease liabilities	967.5	294.5
	(b) Provisions	158.3	63.2
	(c) Other liabilities	219.2	90.0
	Sub-total - Non-current liabilities	**1,345.0**	**447.7**
3	**Current liabilities**		
	(a) Financial Liabilities		
	(i) Lease liabilities	139.1	62.8
	(ii) Trade payables		
	Total outstanding dues of micro and small enterprises	20.4	25.3
	Total outstanding dues of creditors other than micro and small enterprises	7,806.6	4,537.7
	(iii) Other financial liabilities	228.2	252.7
	(b) Provisions	559.2	1,065.3
	(c) Current tax liabilities (net)	54.1	106.4
	(d) Other current liabilities	1,010.5	979.8
	Sub-total - Current liabilities	**9,818.1**	**7,030.0**
	TOTAL - LIABILITIES	**11,163.1**	**7,477.7**
	TOTAL - EQUITY AND LIABILITIES	**19,891.0**	**15,181.2**

PA

AstraZeneca Pharma India Limited Bangalore

Price Waterhouse & Co Chartered Accountants LLP LLPIN AAC-4362 FRN 304026E/E300009 Bengaluru

Initialled For Identification Purpose Only

AstraZeneca Pharma India Limited

Regd Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045

CIN: L24231KA1979PLC003563

Statement of cash flows

(Rs. in millions)

Particulars	For the year ended 31 March 2026 Audited	For the year ended 31 March 2025 Audited
A) Cash flow from operating activities		
Profit before tax	**2,522.0**	**1,563.6**
Non-cash adjustments for :		
Depreciation and amortisation expense	285.8	399.9
(Profit) on sale of property, plant and equipment (net)	(1.6)	(3.2)
Provision for restructuring costs/severance costs	52.5	613.2
Impairment of Other assets	2.9	4.6
Interest income on deposits carried at amortised cost	(232.0)	(315.6)
Employee stock compensation expense	10.9	51.4
Unrealised foreign exchange gain (net)	(9.8)	(7.4)
Allowance for expected credit loss (net)	170.9	6.6
Bad debts written off	9.0	-
Finance costs	44.9	14.6
Operating profit before working capital changes	**2,855.5**	**2,327.7**
Changes in working capital:		
(Increase) / Decrease in trade receivables	(458.1)	(316.8)
(Increase) / Decrease in inventories	(4,788.3)	(3,206.2)
(Increase) / Decrease in loans	4.1	(0.1)
(Increase) / Decrease in other financial assets	(14.2)	(52.6)
(Increase) / Decrease in other assets	223.5	(282.5)
Increase / (Decrease) in trade payables	3,264.0	2,598.1
Increase / (Decrease) in provisions	(522.9)	3.4
Increase / (Decrease) in other financial liabilities	(41.8)	(68.2)
Increase / (Decrease) in other liabilities	159.9	292.7
Cash generated from operations	**681.7**	**1,295.5**
Income taxes paid (net of refund)	(833.1)	(641.9)
Net cash (used in) / generated from operating activities (A)	**(151.4)**	**653.6**
B) Cash flows from investing activities		
Interest income on bank deposits	220.3	318.4
Purchase of property, plant and equipment and intangible assets	(15.6)	(17.5)
Acquistion of right of use asset	(20.5)	-
Proceeds from sale of property, plant and equipment	2.7	7.1
Net cash generated from investing activities (B)	**186.9**	**308.0**
C) Cash flows from financing activities		
Principal repayment of lease liabilities	(74.8)	(41.3)
Interest paid on lease liabilities	(44.2)	(14.0)
Interest paid - others	(0.7)	(0.6)
Dividend paid	(800.0)	(600.0)
Net cash used in financing activities (C)	**(919.7)**	**(655.9)**
D) Net (increase) / decrease in cash and cash equivalents (A+B+C)	**(884.2)**	**305.7**
E) Cash and cash equivalents at the beginning of the year	**5,361.4**	**5,055.7**
F) Cash and cash equivalents at the end of the year (D+E)	**4,477.2**	**5,361.4**
Non-cash investing activities		
- Acquisition of right-of-use assets	883.0	365.3
- Disposal of right-of-use-assets	2.1	7.7
Components of cash and cash equivalents as at the end of the year	**As at 31 March 2026**	**As at 31 March 2025**
Balance with banks :		
Current accounts	89.8	268.1
Demand deposits with original maturity of less than 3 months	4,257.6	5,093.3
Cash in transit	129.8	-
Total cash and cash equivalents	**4,477.2**	**5,361.4**

PA

AstraZeneca Pharma India Limited Bangalore

Price Waterhouse & Co Chartered Accountants LLP FRN 304026E/E300009 Bengaluru

Initialled For Identification Purpose Only

INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of AstraZeneca Pharma India Limited

Report on the Audit of Financial Results

Opinion

1. We have audited the accompanying annual financial results of AstraZeneca Pharma India Limited (the "Company") for the year ended March 31, 2026 and the Statement of assets and liabilities as on that date and the Statement of cash flows for the year ended on that date, attached herewith, which are included in the accompanying 'Statement of financial results for the quarter and year ended 31 March 2026', 'Statement of assets and liabilities' and 'Statement of cash flows' (together referred to as the "financial results") being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations") which has been initialed by us only for identification purposes.

2. In our opinion and to the best of our information and according to the explanations given to us, the financial results:

   (i) are presented in accordance with the requirements of Regulation 33 of the Listing regulations in this regard; and

   (ii) give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 (the "Act") and other accounting principles generally accepted in India, of net profit and other comprehensive income and other financial information of the Company for the year ended March 31, 2026 and the Statement of assets and liabilities and the Statement of cash flows as at and for the year ended on that date.

Basis for Opinion

3. We conducted our audit in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the Act and other applicable authoritative pronouncements issued by the Institute of Chartered Accountants of India. Our responsibilities under those Standards are further described in the 'Auditor's Responsibilities for the Audit of the Financial Results' section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

Board of Directors' Responsibilities for the Financial Results

4. These financial results have been prepared on the basis of the annual financial statements. The Company's Board of Directors are responsible for the preparation and presentation of these financial results that give a true and fair view of the net profit and other comprehensive income and other financial information of the Company and the Statement of assets and liabilities and the Statement of cash flows in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Board of Directors of the

Price Waterhouse & Co Chartered Accountants LLP LLPIN AAC-4362 FRN 304026E/E300009 Bengaluru

Company are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the financial results by the Directors of the Company, as aforesaid.

5. In preparing the financial results, the Board of Directors of the Company are responsible for assessing the ability of the Company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

6. The Board of Directors of the Company are responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities for the Audit of the Financial Results

7. Our objectives are to obtain reasonable assurance about whether the financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial results.

8. As part of an audit in accordance with SAs, we exercise professional judgement and maintain professional skepticism throughout the audit. We also:

   - Identify and assess the risks of material misstatement of the financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

   - Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.

   - Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.

   - Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are

Price Waterhouse & Co Chartered Accountants LLP
LLPIN AAC-4362
FRN 304026E/E300009
Bengaluru

required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

9. We communicate with those charged with governance of the Company regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

10. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

11. The financial results include the results for the quarter ended March 31, 2026 being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year, which were subject to limited review by us.

For Price Waterhouse & Co Chartered Accountants LLP
Firm Registration Number: 304026E/E-300009

Sharmila Ramaswamy
Partner
Membership Number: 215131
UDIN: 26215131ISSDHI6719

Place: Bengaluru
Date: May 26, 2026

AstraZeneca

45 YEARS
Bringing science to patients since 1979

Annexure - A

Sl. No	Particulars	Re-appointment of Ms. Shilpa Divekar Nirula
1	Reason for change Viz. appointment, resignation, removal, death or otherwise	Re-appointment of Ms. Shilpa Divekar Nirula (DIN: 06619353) as an Independent Director of the Company, for a second term of 5 years
2	Date of ~~Appointment/~~ Re-appointment ~~Cessation~~/Term of appointment	December 29, 2026 Term: For a period of five (5) years commencing from December 29, 2026
3	Brief Profile	Ms. Shilpa Divekar Nirula is an accomplished professional with over 28 years of experience, starting in consulting and successfully transitioning to the agriculture and food sector. Shilpa has worked for reputed organizations including Arthur Andersen, KPMG, Bunge Agribusiness, Monsanto and Bayer CropScience in roles of growing responsibility. At Bayer CropScience, Shilpa led Strategy and Commercial Excellence for the Asia-Pacific region and co-led the Global Smallholder Strategy between 2018 and 2020. Shilpa was the CEO and MD of Monsanto India from 2014 to 2018. Prior to her over 12 years stint at Bayer and Monsanto, she was the Head of Strategy & Business Development for Bunge India, a US headquartered multinational involved in oilseeds, commodity trading & foods. Since April 2020, Shilpa has been mentoring businesses to help them turn around, grow, or startup. She holds independent director positions in GMM Pfaudler Limited and is an advisor to Omnivore, an agri-tech focused venture capital fund. Shilpa has recently co-founded AGVAYA LLP, a consulting and advisory services firm committed to assist participants across the agriculture and food value chains. She is a post-graduate in Commerce, a Cost Accountant, Chartered Accountant and an MBA, started her career in 1996 at Arthur Andersen and KPMG and gained significant experience serving clients in diverse industry sectors.
4	Disclosure of Relationships between Directors	Ms. Shilpa Divekar Nirula is not related to any of the Directors of the Company.
5	Affirmation pursuant to circular no. LIST/COMP/14/2018-19 and circular no. NSE/CML/2018/02 dated June 20, 2018 issued by BSE and NSE	Ms. Shilpa Divekar Nirula is not debarred from holding the office of Director by virtue of any SEBI Order or any such Authority.

AstraZeneca

45 YEARS
Bringing science to patients since 1979

Annexure - B

Sl. No	Particulars	Appointment of M/s. BSR & Co. LLP, Chartered Accountants as the Statutory Auditors of the Company
1	Reason for change Viz. appointment, resignation, removal, death or otherwise	Pursuant to the retirement of M/s. Price Waterhouse Cooper, Chartered Accounts as Statutory Auditor of the Company at the ensuing Annual General Meeting of the Company, it is proposed to appoint M/s. BSR & Co. LLP, Chartered Accountants as the Statutory Auditors of the Company.
2	Date of appointment ~~Cessation~~/Term of appointment	May 26, 2026 Term: For a period of five (5) years commencing from the conclusion of the ensuing Annual General Meeting ('AGM'), i.e. the 47th AGM of the Company till the conclusion of the 52nd AGM to be held in the year 2031, subject to the approval of the shareholders.
3	Brief Profile	B S R & Co. was constituted on March 27, 1990 as a partnership firm and was thereafter converted into limited liability partnership i.e. B S R & Co. LLP, on 14 October 2013. The registration no. of the firm is 101248W/W-100022. The registered office of the firm is at 14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Centre, Western Express Highway, Goregaon (East), Mumbai- 400063. B S R & Co. LLP is a member entity of B S R & Affiliates, a network registered with the Institute of Chartered Accountants of India. The firm has over 4000 staff and 170+ Partners and has offices across 14 locations. The firm audits various companies listed on stock exchanges in India including companies in the pharmaceuticals sector.

AstraZeneca

Press release

AstraZeneca Pharma India Limited marks consistent 33% growth as the Company announces its annual results for FY 2025-2026

- *Total Revenue reached INR. 22,755.8 Mn in the FY 2025-26*
- *11 regulatory approvals for medicines and indications in FY 2025-26, reinforcing leadership across therapy areas and accelerating the delivery of innovative medicines across India*

Bangalore, 26 May 2026: AstraZeneca Pharma India Limited (the Company), a science-led biopharmaceutical company, today announced its full-year results for the financial year (FY) ended 31 March 2026. The Company maintained strong momentum during the year and delivered an 33% year-on-year growth in total revenue, reflecting sustained performance across its therapy areas and continued progress in bringing innovative medicines to patients in India.

Financial Performance Summary:

(Value in INR Mn)

Summary	Q4 (Jan- Mar '26)	Full FY Apr '25- Mar '26
Total revenue from Operations	5,786.1	22,755.8
Profit before exceptional item and tax	592.2	2,574.5
Profit after exceptional item and tax	448.8	1,875.2

Summary		Full FY Apr '25- Mar '26
TA-wise performance	**Oncology**	16,100.9
	Biopharmaceuticals (CVRM, R&I and V&I)	5,243.2
	Rare Disease	214.6

During FY 2025-26, AstraZeneca India recorded total revenue from operations of INR 22,755.8 Mn, supported by continued growth in Oncology and Biopharmaceuticals, as well as progress in Rare Disease. The year was also marked by 11 new regulatory approvals for medicines and indications, underscoring the Company's commitment to scientific innovation, bringing them to the country at an accelerated pace and its focus on addressing unmet patient needs across India.

Bhavana Agrawal, Chief Financial Officer & Director of the Company, said: "FY 2025-26 was a year of strong and consistent growth for AstraZeneca India, underpinned by the resilience of our business, the strength of our science-led portfolio, and disciplined execution across the organisation. Our performance reflects not only commercial momentum, but also our continued commitment to creating sustainable value through innovation, responsible growth, and meaningful impact for patients, society, and the planet."

Praveen Rao Akkinepally, Managing Director, AstraZeneca India, added: "At AstraZeneca, science is at the heart of everything we do. Our FY 2025-26 performance reflects the progress we are making, accelerating the delivery of innovative medicines across key therapy areas and advancing our ambition to transform patient outcomes in India. With a strong pipeline and a clear sense of purpose, we remain focused on addressing unmet medical needs, advancing the healthcare ecosystem, and creating long-term impact through science-led innovation."

Key milestones: During FY '25-26, the Company achieved several important regulatory and business milestones that strengthened its portfolio and expanded patient access to innovative therapies in India.

- **Durvalumab – endometrial cancer**: Received regulatory approval from CDSCO to import for sale and distribution of Durvalumab solution for infusion for two additional indications. Durvalumab in combination with carboplatin and paclitaxel is now indicated for first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy; followed by maintenance treatment with Durvalumab in combination with Olaparib in endometrial cancer that is *pMMR*.
- **Durvalumab – muscle invasive bladder cancer (MIBC)**: Received regulatory approval from CDSCO to import for sale and distribution of Durvalumab Solution for Infusion 120 mg/2.4 ml and 500 mg/10 ml for an additional indication as adjuvant treatment following radical cystectomy for adult patients with MIBC.
- **Eculizumab – rare diseases**: Launched **Eculizumab**, the first anti-complement therapy approved in India by CDSCO for the treatment of *atypical Haemolytic Uremic Syndrome (aHUS)* and *Paroxysmal Nocturnal Hemoglobinuria (PNH)*, marking a significant milestone in rare diseases.
- **Osimertinib – NSCLC**: Received regulatory approval to import for sale and distribution of Osimertinib tablets for an additional indication in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with locally advanced or metastatic NSCLC with *EGFR exon 19 deletions or exon 21 (L858R)* substitution mutations.

- **Trastuzumab deruxtecan – HER2 spectrum expansion**: Received regulatory approval from CDSCO to import for sale and distribution of **trastuzumab deruxtecan** for an additional indication in *HER2-low* and *HER2-ultralow* metastatic breast cancer patients who have received at least one endocrine therapy in the metastatic setting.
- **Osimertinib – NSCLC (stage III, monotherapy)**: Gained CDSCO regulatory approval for an additional indication of **Osimertinib** as monotherapy for import for sale and distribution for the treatment of patients with locally advanced, unresectable (stage III) NSCLC with *EGFR exon 19 deletions or exon 21 (L858R)* substitution mutations whose disease has not progressed during or following platinum-based chemoradiation therapy.
- **Benralizumab – EGPA**: Received regulatory approval from CDSCO to import for sale and distribution of **Benralizumab** for an additional indication as an add-on treatment for adult patients with relapsing or refractory *eosinophilic granulomatosis with polyangiitis (EGPA)*.
- **Sodium Zirconium Cyclosilicate (5g/10g)** – Hyperkalaemia: Received CDSCO permission for import and sale in India. The therapy is indicated for the management of hyperkalaemia in adults, particularly associated with cardiovascular, renal, and metabolic conditions *(in partnership with Sun Pharma)*.
- **Durvalumab – Gastric Cancer**: Received regulatory approval from CDSCO in January 2026 for Durvalumab in combination with FLOT chemotherapy as perioperative treatment for adults with resectable gastric or gastroesophageal junction adenocarcinoma, based on the MATTERHORN trial demonstrating improved event-free survival.
- **Durvalumab – Liver Cancer:** Durvalumab plus tremelimumab received expanded regulatory approval or recommendation from CDSCO in March 2026 for first-line treatment of unresectable hepatocellular carcinoma, following the HIMALAYA trial results showing significant overall survival benefit over sorafenib.

Recognitions:

- Pharma Company of the Year at ET RePharma Awards
- Medical Excellence Award for Rare Disease at OPPI India
- Recognised as Top Employer India 2025
- Marketing Excellence Award for Hyperkalaemia & Kidney Care, Biopharmaceuticals at OPPI India
- OPPI Medical Excellence Award 2025 for Medical Affairs, Regulatory Excellence, and Clinical Trials.
- 1st Place in 2025 SAS Customer Recognition Awards for innovative use of Real-World Data in clinical trials.
- ET HRWorld EX Awards 2025: AstraZeneca Pharma India awarded for Exceptional Employee Experience (Large Scale), recognizing our progress in I&D.
- Excellence in Precision Biopharma Solutions at the VOH National Healthcare Awards 2025.

About AstraZeneca Pharma India Ltd

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in four therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory and Rare Disease. AstraZeneca operates in

over 100 countries and its innovative medicines are used by millions of patients worldwide. Completing its 45 years in India, AstraZeneca Pharma India Limited is headquartered at Bengaluru, Karnataka in India and has a workforce of over 600 employees across the country committed to deliver great medicines to patients through innovative science and global excellence in development and commercialization. For more information, please visit our website: https://www.astrazeneca.in/ or follow us on LinkedIn: AstraZeneca India.

Media contact: M Sindhu: sindhu.manivannan@astrazeneca.com